Clinical trial
AVONEX® Combination Trial - "ACT"
NCT00112034 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00112034 |
|---|---|
| Title | AVONEX® Combination Trial - "ACT" |
| Official title | A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy. |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention type | Drug |
| Interventions | Methotrexate, IV methylprednisolone |
| Enrollment | 350 |
| Start date | Jun 1, 2003 |
| Primary completion | Jun 1, 2006 |
| Completion | May 1, 2007 |
| First posted | May 30, 2005 |
| Last update posted | May 9, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: